Ernexa Therapeutics Inc. (ERNA): R&D Expense
$4.16M
Year ended 2025-12-31
$6.42M
Trailing 12 months to 2026-06-30
-26.3%
3-year compound annual growth
+1.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.16M | -9.7% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $4.60M | -22.2% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $5.92M | -43.0% | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | $10.39M | -18.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $12.71M | +221.6% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $3.95M | n/a | 2022-07-01, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $4.16M | -9.7% |
| CDT Equity Inc. (CDT) | 2025-12-31 | $5.05M | +49.6% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $4.09M | -71.1% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $17.22M | +11.2% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
Compare ERNA, CDT, JUNS, AEON side by side · Screen every company in Pharmaceutical Preparations ↗